Articles from The NIMML Institute

The NIMML Institute (“NIMML”), a 501 (c)(3) nonprofit research institute dedicated to the discovery of novel precision medicines for infectious, inflammatory and autoimmune diseases, today announced the publication of new peer-reviewed article in the International Journal of Radiation Biology titled, “Immunometabolic Mechanisms of Ionizing Radiation in a Mouse Model of Gastrointestinal Acute Radiation Syndrome.” The study is a comprehensive, system-wide transcriptional analysis providing new insights into the response mechanisms underlying ionizing radiation-induced intestinal damage and subsequent mortality, along with identification of novel immunometabolic mechanisms with strong potential for therapeutic development in gastrointestinal acute radiation syndrome (“GI-ARS”). The publication of this research, which is funded by the Defense Threat Reduction Agency (“DTRA”) follows the presentation of the associated abstract, “Colonic immunometabolic host response mechanisms to ionizing radiation in a mouse model of acute radiation syndrome” by NIMML at the IMMUNOLOGY2026 conference.

The NIMML Institute, (“NIMML”), a 501 (c)(3) nonprofit research institute dedicated to the discovery of novel precision medicines for infectious and autoimmune diseases, today announced publication of four new case studies in the Annual Review of Biomedical Data Science. Together, they demonstrate how the A.I.-powered TITAN-X Precision Medicine Platform (“TITAN-X”) has been leveraged to identify therapeutic targets and fueled the development of multiple therapeutic program pipelines that have successfully entered clinical testing.

The NIMML Institute, (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for inflammatory and autoimmune diseases, will present results from two novel studies for omilancor, a once-daily, oral, best- and first-in-class therapy in Phase 3 clinical development for ulcerative colitis (“UC”) and Phase 2 for Crohn’s disease, at Digestive Disease Week 2025. DDW 2025 will be held at the San Diego Convention Center from May 3-6, 2025.

The NIMML Institute, (“NIMML”), a 501 (c)(3) nonprofit research institute dedicated to the discovery of novel precision medicines for infectious and autoimmune diseases, today announced publication of positive Phase 1 clinical results for NIM-1324, a first- and potentially best-in-class once-daily, oral, systemically distributed LANCL2 agonist therapeutic for the treatment of Systemic Lupus Erythematosus (SLE). The results, published in Clinical and Translational Science, the journal of the American Society for Clinical Pharmacology and Therapeutics, validate NIM-1324 and the LANCL2 pathway as a safe and well-tolerated novel mechanism of action with no dose-limiting toxicities.

The NIMML Institute (“NIMML”), a 501 (c)(3) nonprofit institute dedicated to the discovery of novel precision medicines for autoimmune diseases, today recognized its co-founders, Dr. Josep Bassaganya-Riera and Dr. Raquel Hontecillas, and scientific director Dr. Andrew Leber for their leadership in the discovery and development of NX-13 that enabled today’s acquisition of Landos Biopharma, Inc. (“Landos”) by AbbVie, Inc. (NYSE: ABBV) (“AbbVie”). Dr. Bassaganya-Riera founded Landos in 2017 and led the Company’s subsequent growth from inception through multiple rounds of private funding, a successful IPO, growth as a NASDAQ-listed biopharma company with market capitalization in excess of $625 million, 7 INDs and 17 therapeutic development programs, including the successful clinical development of NX-13 and omilancor for the treatment of ulcerative colitis (UC) and potentially other autoimmune diseases.